SLC5A2 and hydrops fetalis: In both trials, SGLT2 inhibitors reduced the composite outcome of HF hospitalization or CV death, DAPA-HF: HR, 0.74; 95% CI (0.65 to 0.85) and EMPEROR-Reduced: HR, 0.75; 95% CI (0.65 to 0.86) although the duration of follow-up was relatively shorter in the EMPEROR-Reduced trial.